Preparation, quality control and biodistribution studies of [ 67Ga]-DOTA-anti-CD20

Radiochimica Acta

Volumn 96, Issue 3, 2008, Pages 167-174

  Jalilian, A R ^a   Mirsadeghi, L ^b   Haji Hosseini, R ^b   Khorrami, A ^a  

^a AGRICULTURAL MEDICAL AND INDUSTRIAL RESEARCH SCHOOL   (Iran)

^b PAYAME NOOR UNIVERSITY   (Iran)

Author keywords

DOTA; Gallium 67; Quality control; Radiolabeling; Rituximab

Indexed keywords

EID: 41149156917     PISSN: 00338230     EISSN: None     Source Type: Journal    
DOI: 10.1524/ract.2008.1494     Document Type: Article

References (21)

1. Witzig, T. E., White, C. A., Wiseman, G. A., Gordon, L. I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R. J., Spies, S., Silverman, D. H., Parker, E., Grillo-Lopez, A. J.: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 17, 3793 (1999).
2. Eary, J. F., Press, O. W., Badger, C. C., Durack, L. D., Richter, K. Y., Addison, S. J., Krohn, K. A., Fisher, D. R., Porter, B. A., Williams, D. L.: Imaging and treatment of B-cell lymphoma. J. Nucl. Med. 31, 1257 (1990).
3. Knox, S. J., Levy, R., Miller, R. A., Uhland, W., Schiele, J., Ruehl, W., Finston, R., Day-Lollini, P., Goris, M. L.: Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res. 50, 4935 (1990).
4. Kyle, R. A., Gertz, M. A., Greipp, P. R., Witzig, T. E., Lust, J. A., Lacy, M. Q., Therneau, T. M.: Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 93, 1062 (1999).
5. Dietlein, M., Pels, H., Schulz, H., Staak, O., Borchmann, P., Schomäcker, K., Fischer, T., Eschner, W., Pogge von Strandmann, E., Schicha, H., Engert, A., Schnell, R.: Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur. J. Haematol. 74, 348 (2005).
6. Chappell, L. L., Ma, D., Milenic, D. E., Garmestani, K., Venditto, V., Beitzel, M. P., Brechbiel, M. W.: Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N,N,N-tetraacetic acid for radiolabeling proteins. Nucl. Med. Biol. 30, 581 (2003).
7. Hoffend, J., Mier, W., Schuhmacher, J., Schmidt, K., Dimitrakopoulou- Strauss, A., Strauss, L. G. Kinscherf, E. R. M., Haberkorna, U.: Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo. Nucl. Med. Biol. 32, 287 (2005).
8. Ugur, O., Kothari, P. J., Finn, R. D., Zanzonico, P., Ruan, S., Guenther, I., Maecke, H. R., Larson, S. M.: Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl. Med. Biol. 29, 147 (2002).
9. 225Ac radioimmunopharmaceuticals. Appl. Radiat. Isotopes 57, 841 (2002).
10. 2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl. Med. Biol. 30, 101 (2003).
11. 212Pb. Nucl. Med. Biol. 27, 93 (2000).
12. 99mTc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent. Eur. J. Nucl. Med. Mol. Imaging. 33, 53 (2006).
13. 177Lu-DOTA- lanreotide: A novel tracer as a targeted agent for tumor therapy. Nucl. Med. Biol. 31, 753 (2004).
14. Mier, W., Hoffend, J., Kramer, S., Schuhmacher, J., Hull, W. E., Eisenhut, M.: Conjugation of DOTA using isolated phenolic active esters: The labeling and biodistribution of albumin as a blood-pool marker. Bioconjug. Chem. 16, 237 (2005).
15. 90Y-DOTA for potential application in intra-vascular radionuclide therapy. Appl. Radiat. Isotopes 57, 313 (2002).
16. Laemmli, U. K.: Cleavage of structural proteins during assembly of the head of the bacteriophage T4. Nature (London) 227, 680 (1970).
17. 18F]-N-succinimidyl 4-(fluoromethyl)benzoate for protein labeling. Appl. Radiat. Isotopes 45, 1155 (1994).
18. www.pathologyoutlines.com/lymphoma.html.
19. Smith-Jones, P., Solit, D. B., Akhurst, T., Afroze, F., Rosen, M., Larsen, S. M.: Imaging of pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nature Biotechnol. 22, 701 (2004).
20. Press, O. W., Leonard, J. P., Coiffier, B., Levy, R., Timmerman, J.: Immunotherapy of non-Hodgkin's lymphomas. Hematology Am. Soc. Hematol. Educ. Program. 221 (2001) Review.
21. Rituxan® (Roche) pamphlet, CCO Formulary, revised 2004/2005, Chapt. B, p. 1.